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SUBMISSION TO THE ACIP INQUIRY ON THE  
INNOVATION PATENT - EXCLUSION OF PLANT AND 
ANIMAL SUBJECT MATTER 
MATTHEW RIMMER 
 
The Australian Centre for Intellectual Property in Agriculture (ACIPA) is a research centre 
based at the law schools of the Australian National University in Canberra and Griffith 
University in Brisbane.  It commenced operations in September 2000 to undertake research in 
issues relating to intellectual property law, and apply that knowledge to the scientific 
community and industry and rural bodies. The Centre's ultimate purpose is to foster an active 
environment in which Australia better protects and capitalises the products of research and 
innovation.   It has particular expertise in both patent law and plant breeder's rights. 
 
ACIPA is keen to consider the operation of s 18 (3) and 18 (4) of the Patents Act 1990 (Cth), 
as amended by the Patents Amendment (Innovation Patents) Act 2000 (Cth), which stipulates 
that certain inventions are outside the scope of the innovation patent.  S 18 (3) provides that 
"for the purposes of an innovation patent, plants and animals, and the biological processes for 
the generation of plants and animals, are not patentable inventions."  However, s 18 (4) notes 
that "subsection (3) does not apply if the invention is a microbiological process or a product of 
such a process". 
 
ACIPA submits that there are strong justifications for the exclusion of plant and animal subject 
matter from the scope of the innovation patent. There is currently no gap in intellectual property 
protection for inventions involving plant subject matter, because of the operation of the plant 
breeder's rights system. Animal subject matter is controversial and better left out of the scope 
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of the innovation patent.  The innovation patent would have harmful effects upon rural and 
regional communities if it were to include plant and animal subject matter.  It also has the 
potential to harm research and development in Australia in relation to plants and animals. There 
is a need for a comprehensive review of the operation of the innovation patent, as well as the 
plant breeder's scheme, before any legislative amendments are implemented. 
 
ACIPA would like to make the following specific submissions: 
 
1. There are still reservations about the constitutional validity of innovation patents - 
whereas there are no such doubts about the plant breeder's rights system. 
 
2. The registration system for innovation patents is inferior to that demanded under the 
plant breeder's rights system because there is no requirement for substantive examination 
before the grant of rights. 
 
3. The standard of an "innovative step" is vague and uncertain - in comparison to the 
requirements of distinctiveness, uniformity, and stability under plant breeder's rights. 
 
4. The innovation patent regime fails to provide safeguards for the public interest in access 
to plants - unlike the plant breeder's rights system, which has a range of exceptions dealing 
with farmer-saved seed, among other things. 
 
5. Patent protection of animal subject matter is controversial. 
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6. The innovation patent need not include plant and animal subject matter because of any 
international obligations.  
 
1. Constitutional Basis of Legislation 
 
Both innovation patents and plant breeder's rights are on the penumbra of traditional regimes 
of intellectual property.  In the past, there have been doubts expressed about the constitutional 
validity of the legislation relating to such subject matter.  
 
There are lingering reservations about the constitutional validity of the system of innovation 
patents. Glenn McGowan observes:  "The only basis for doubt would be if the intended (as 
opposed to what seems to be the actual) requirements of the new amendments for innovation 
patentability were successful and were in fact held to be less than the inventive step required 
for a standard patent".1  There might also be concerns about whether innovation patents are 
within the scope of "patents of innovation" under the intellectual property power of the 
Constitution - given that substantive examination is not required at the stage of registration.  
The constitutional validity of the innovation patent regime will remain uncertain until the High 
Court has the opportunity to review the legislation. 
 
By contrast, the High Court of Australia has confirmed the constitutional validity of the plant 
breeder's rights regime.  In Grain Pool of Western Australia v Commonwealth, the plaintiff, 
the Grain Pool of West Australia, challenged the constitutional validity of the Plant Variety 
                                                            
1  McGowan, G.  "The New Innovation Patent System:  Will It Work?", Law Institute Journal, February 
2002, p. 64-67. 
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Rights Act 1987 (Cth) and the Plant Breeders’ Rights Act 1994 (Cth).2  The defendants argued 
that the legislation was supported by the intellectual property power and the external affairs 
power of the Constitution.  
 
The High Court rejected the submission of the State of Western Australia that the rights 
conferred by the Plant Variety Rights Act 1987 (Cth) and the Plant Breeder's Rights Act 1994 
(Cth) amounted to rights “by way of positive authority to sell and export the protected variety”.  
It held that plant variety rights and plant breeder’s rights are negative rights, like those found 
under patent law, which give the rights-holder the power to exclude others from using the 
particular plant material.   
 
The High Court held that the Plant Variety Rights Act 1987 (Cth) and the Plant Breeders’ 
Rights Act 1994 (Cth) were valid under the intellectual property power under the Constitution.  
The joint judgment highlighted historical studies into the development of intellectual property. 
It considered the evolution of common law and statute law.  It undertook a close reading of the 
Plant Variety Protection Act 1987 (Cth) and the Plant Breeder's Rights Act 1994 (Cth).  It 
concluded that plant variety rights do indeed belong within the ambit of “patents of invention”.  
The High Court found it unnecessary to consider the application of the external affairs power 
to the legislation. 
 
Given this broad interpretation of the intellectual property power, it would seem that the 
Federal Government has the power to legislate with respect to plant breeder's rights.   
 
                                                            
2  Grain Pool of Western Australia v Commonwealth (2000) 46 IPR 515 
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2. Registration 
 
The innovation patent has replaced the petty patent as a lower tier patent to supplement the 
standard patent system. Essentially, this scheme offers protection for a maximum term of eight 
years in respect of inventions that display an innovative step. Substantive examination will 
only occur if directed by the Commissioner of Patents or requested by the patent owner or a 
third party or if there is an infringement suit. 
 
The credibility and legitimacy of the registration system for innovation patents has come under 
question.  Infamously, a patent attorney called John Keogh was issued with an innovation 
patent for a "circular transportation facilitation device".3  He said that he patented the wheel in 
order to prove that the innovation patent system was flawed because it did not need to be 
examined by the patent office.  John Keough observed: "The patent office would be required 
to issue a patent for anything.  All they're doing is putting a rubber stamp on it ".4  This 
controversy cannot be dismissed as a mere hoax.  It highlights problems both with the operation 
of the innovation patent system, and the public perceptions of the legitimacy of the regime.  As 
Glenn McGowan notes:  "There remain problems - both conceptual and mechanical - with the 
new system".5 
 
Daniel Stewart comments: "The innovation patent presents the potential to impose considerable 
costs on the innovation process, particularly the cumulative and supplementary innovation that 
                                                            
3  Cochrane, N.  "Melbourne Man Patents The Wheel", The Age, 2 July 2001. 
4  Ibid. 
5  McGowan, G.  "The New Innovation Patent System:  Will It Work?", Law Institute Journal, February 
2002, p. 64-67. 
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characterises much of the development in areas such as biotechnology, e-commerce and 
informatic databases.  The lack of formal examination may lead to greater uncertainty about 
the validity of such patent, particularly if a different approach is to be advocated for the 
interpretation of standard and innovative patents with respect to questions of application".6 
 
By contrast, the scheme established under the Plant Breeder's Rights Act 1994 (Cth) has a 
reputation for rigour and integrity.  The scheme uses breeder testing to establish the 
distinctness, uniformity and stability of new varieties. The breeder or their agent carries out 
comparative trials, using UPOV technical guidelines, to establish that each new variety satisfies 
criteria of distinctiveness, uniformity and stability. To ensure technical rigour, the Plant 
Breeder's Rights Office requires all applicants to engage the services of an accredited qualified 
person.  The Qualified Person, in collaboration with the Plant Breeder's Rights Office, accepts 
responsibility for all aspects of the comparative trial, including the choice of comparative 
varieties, experimental design, collection of data, statistical analysis and preparation of a 
description of the variety. The Plant Breeder's Rights Office publishes a description and 
photograph of each variety in the Plant Varieties Journal. Publication allows a breeder's peers 
to object to the granting of plant breeder's rights, informs industry and gives the public an 
opportunity to comment on individual applications. 
 
The expansion of the innovation patent system to include plants and animal subject matter 
would create confusion and uncertainty amongst rural and regional communities.  There would 
be a concern amongst plant breeders that they would need to apply for both an innovation patent 
                                                            
6  Stewart, D. "Patenting Innovations - Will it work?", Published proceedings of the Technology Transfer 
and Innovation 2001 Conference, Brisbane, Australia, 26-28 September 2001. 
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and plant breeder's rights.   In "Patenting Innovations", Daniel Stewart raises concerns about 
the impact of innovation patents on research and development in the field of biotechnology: 
 
The ability to quickly and easily obtain an innovation patent will only add to the concerns over the use 
of patents in the biotechnology area to stifle or add costs to research and prevent the development of 
basic and public research.  As discussed above, Innovation patents can lead to uncertainty over the 
protected material, patent pools, fragmentation of ownership of enabling technology, defensive patents 
and blocking patents. They also facilitate the imposition of reach-through licensing and extend their 
potential reach into the downstream markets.  The modular nature of many developments in 
biotechnology, the importance of enabling technologies, the uncertainty over the scope of any research 
exception to infringement, and the potential of identified and isolated genes or gene fragments only adds 
to the potential of the innovation patent to impose significant costs on cumulative and subsequent 
research and development in this area.7 
 
The accompanying increase in transaction costs would reduce the incentives for plant breeders 
to create new plant varieties.  Furthermore innovation patents generate inherently insecure 
rights, and there would be uncertainties among breeders about the validity of innovation patents 
in infringement proceedings. 
 
3. Threshold of Innovation 
 
Historically, the patent system has been ill-adapted to plant varieties.  Plant breeders first 
sought protection under the industrial patent system.  However, a number of technical 
difficulties were encountered in seeking to apply the rules of a system designed to protect 
technical inventions to plant varieties, which were thought not to precisely reproduce 
                                                            
7  Ibid. 
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themselves, and whose appearance can vary depending upon the environment in which they 
are grown. Margaret Llewellyn observes:   
 
There were two main reasons why the patent system was seen as inappropriate.  First, plant material was 
not regarded as capable of meeting the requirements of novelty, inventive step and disclosure.  Secondly, 
it was not thought to be in the public interest to permit such an extensive monopoly over plant varieties, 
given their communal importance.  Underlying this was the view that it was desirable to retain, in so far as 
it was possible, the tradition of free exchange of new plant material between plant breeding institutes.  This 
would ensure the widest possible dissemination and use of the new combinations of genetic information.8 
 
For these reasons, it was decided to introduce a special form of protection which would be 
designed to support a specific industry, the plant variety right.   
 
The innovation patent can be used to protect inventions that are incremental, or small advances 
to devices, substances, methods or processes, that display an "innovative step". S 7 (4) of the 
Patents Act 1990 (Cth) provides that “an invention is to be taken to involve an innovative step 
when compared with the prior art base unless the invention would, to a person skilled in the 
relevant art, in the light of the common general knowledge as it existed in the patent area before 
the priority date of the relevant claim, only vary from the kinds of information set out in 
subsection (5) in ways that make no substantial contribution to the working of the invention”. 
 
The invention must also satisfy the other criteria for a valid standard patent, such as being 
"new", "useful", and a "manner of manufacture". S 18 (1A) of the Patents Act 1990 (Cth) 
                                                            
8  Llewelyn, M.  "The Legal Protection Of Biotechnological Inventions:  An Alternative Approach", 
European Intellectual Property Review, 1997, Vol. 19 (3), p. 115. 
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provides that “an invention is a patentable invention for the purposes of an innovation patent if 
the invention, so far as claimed in any claim: (a) is a manner of manufacture within the meaning 
of section 6 of the Statute of Monopolies; (b) when compared with the prior art base as it existed 
before the priority date of the claim: (i) is novel; and (ii) involves an inventive step; and (c) is 
useful; and (d) was not secretly used in the patent area before the priority date of that claim by 
on or behalf of, or with the authority of, the patentee or nominated person or patentee’s or 
nominated person’s predecessor to the title." 
 
However, there are problems with the definition and interpretation of an "innovative step".  
Glenn McGowan comments: 
 
There is real doubt about whether the new legislation actually does impose or require the lower level of 
invention that was intended...  It seems on any reasonable view that the new s 7 (4) either adds nothing 
(because what it adds is less than that required for an invention the subject of the standard patent) or adds 
something, in which case the height of the hurdle for obtaining a patent has been raised.9 
 
Similarly, Daniel Stewart is concerned as to how the standard of an "innovate step" will interact 
the requirement of "novelty":  "It is open to question to what extent this will go beyond the 
novelty test as applied in the case of a standard patent".10  He adds:  "Of more concern is the 
extent to which an innovative step will constitute a significant requirement".11  Courts may 
struggle in making fine distinctions between an "innovative step", and the threshold 
                                                            
9  McGowan, G.  "The New Innovation Patent System:  Will It Work?", Law Institute Journal, February 
2002, p. 64-67. 
10  Stewart, D. "Patenting Innovations - Will it work?", Published proceedings of the Technology Transfer 
and Innovation 2001 Conference, Brisbane, Australia, 26-28 September 2001. 
11  Ibid. 
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requirement of inventiveness, the need for novelty, as well as the standard of an innovative 
step. 
 
Much will depend on the first test case of the innovation patent.12  DataDot Technology has 
launched legal action in the Federal Court, claiming that a rival company, Alpha Microtech, 
has infringed its innovation patent.  DataDot has developed an invention which sprays cars 
with more than 10,000 'micro-dots' to deter car thieves from breaking up stolen cars to rebuild 
them or sell their parts.  Alpha is offering a similar system, called the SmartDot security 
marking and identification system.  The pending Federal Court judgment may give a better 
idea of the operation of the innovation patent system. 
 
Nonetheless there is still concern as to how this vague standard of an "innovative step" would 
be applied to plant and animal subject matter.  IP Australia have released guidelines in respect 
of obtaining standard patents for plants.13 It advises that the range of patentable subject matter 
for plants.    A plant variety is patentable under the Patents Act 1990 (Cth) if it meets the 
standard requirements for patentability.  Furthermore, a patent application in respect of a plant 
variety must be capable of written description.  It must be replicable based on a written 
description provided in a patent specification.  Full description of the plant or plant variety 
means an inclusion of the full morphological, biochemical and taxonomic characteristics of the 
organism known to the applicant.  It also includes a full description of any scientific testing 
characteristics  if available.  There must be sufficient clear information to enable the specialist 
to fill in any missing gaps in the description of the invention without conducting lots of 
experimentation or resorting to invention to discover the conditions necessary for the work.  
                                                            
12  Kitney, D.  "News - First Test Of Innovation Patent Status", Australian Financial Review, 5 August 2002. 
13  IP Australia.  "Australian Patents For Plants", November 1998. 
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However, such requirements are a little vague as compared to the standards necessary for plant 
varieties under the Plant Breeder's Rights Act 1994 (Cth). 
 
The issues paper displays a poor understanding of the requirements of the Plant Breeder's 
Rights Act 1994 (Cth).  S 43 (1) provides that "a plant variety in which an application for PBR 
is made registrable if the variety has a breeder, and the variety is distinctive, uniform, stable, 
and has not been exploited.  First there is a need to identify the breeder for the purposes of the 
plant breeder's rights.  Second, a plant variety must be distinct in order to be registrable.14  A 
plant variety is distinct if it is clearly distinguishable from any other variety whose existence is 
a matter of common knowledge.15  Third, a plant variety is uniform if, subject to the variation 
that may be expected from the particular features of its propagation, it is uniform in its relevant 
characteristics on propagation.16   The required standard of uniformity for each type of 
propagation is set out under the UPOV technical guidelines.  Fourth, the  plant variety is stable 
if its relevant characteristics remain unchanged after repeated propagation or reproduction.17 
Breeders of varieties propagated from seed need to demonstrate stability by including two 
generations in the comparative trial.  Finally, the plant variety must not have been exploited, 
or recently exploited.18 
 
There are further requirements that might need to be satisfied in respect of essential derivation.  
A plant variety is taken to be an essentially derived variety of another plant variety if it is 
                                                            
14  S 43 (1) of the Plant Breeder's Rights Act 1994 (Cth) 
15  S 43 (2) of the Plant Breeder's Rights Act 1994 (Cth) 
16  S 43 (3) of the Plant Breeder's Rights Act 1994 (Cth) 
17  S 43 (4) of the Plant Breeder's Rights Act 1994 (Cth) 
18  Sun World International Inc v Registrar of Plant Breeder's Rights 1998 
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predominantly derived from that other plant variety; and retains the essential characteristics 
that result from the genotype; and it does not exhibit any important (as distinct from cosmetic) 
features that differentiate it from that other variety.19 The criteria of essential derivation plays 
an important role in mediating between first breeders and later breeders.  It also leaves space 
open for the operation of standard patents in respect of biotechnological inventions. 
 
One possible flow-on consequence of changing the scope of the innovation patent would be a 
reconsideration of the criteria of essential derivation.  Conceivably, the Plant Breeder's Rights 
Office could relax the criteria of essential derivation in order to increase the scope of possible 
applications for plant breeder's rights.20  In so doing, there would be a much greater incentive 
for researchers in the field of biotechnology to obtain protection under plant breeder's rights 
than the much more expensive system of standard patents. 
 
4. Exceptions 
 
There is a dearth of defences in respect of patent infringement of both innovation patents and 
standard patents.  First of all, there is no defence to patent infringement in respect of 
experimental use in the context of Australia.  Thus plant breeders engaging in experimental 
research might be exposed to claims of patent infringement.  Second, there is no special 
provision for agricultural products under the Patents Act 1990 (Cth).  Thus saving farm seed 
could amount to patent infringement.  Third, there is no scheme for equitable remuneration 
under the Patents Act 1990 (Cth).  This may impede the development of end-point royalties in 
                                                            
19  S 4 of the Plant Breeder's Rights Act 1994 (Cth) 
20  Draft Report of the Expert Panel on Breeding.  "Clarification Of Plant Breeding Issues Under the Plant 
Breeder's Rights Act 1994 (Cth)".  February 2002. 
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the context of the grains industry.  Fourth, the compulsory licensing provisions under the 
Patents Act 1990 (Cth) are long, complex, and unwieldy.21  As a result, they have laid largely 
dormant.  It is therefore unlikely that they would be of use to rural and regional communities.   
Finally, the court can refuse to withhold remedies in cases of innocent infringement.22  
However, the circumstances in which they can exercise such a discretion are limited. 
 
The case of Monsanto v Percy Schmeiser illustrates some of the limitations of the patent system 
in dealing with agricultural biotechnology.23 Monsanto brought an action for patent 
infringement against Percy Schmeiser, a 70 year old farmer from Saskatchewan Canada.  He 
had grown canola since the 1950’s.  Monsanto claimed that in 1998 the defendants planted 
glyphosate-resistant seeds to grow a crop of canola, for harvest, having a gene or cell that is 
the subject of the plaintiff’s patent. Justice McKay held that the growing and sale of Roundup 
tolerant canola by the defendants infringed the exclusive rights of the plaintiffs to use the 
patented gene and cell. His Honour found it immaterial that Percy Schmeiser was a passive 
infringer.  Commenting upon the case, Professor Brad Sherman said that patent law must have 
stronger defences built into it, like the farmer’s privilege in plant breeder’s rights.24 He said it 
was necessary to shift the balance between patent owners and patent users. 
 
                                                            
21  S 133 of the Patent Act 1990 (Cth) 
22  S 123 of the Patent Act 1990 (Cth) 
23 Monsanto v Percy Schmeiser (2001) FCT 256  
24  Sherman, B.  Biological Inventions and the Problem of Passive Infringement, Australian Intellectual 
Property Journal, August 2002, Vol. 13 (3), p. 146.  See also Lee, M. and Burrell, R.  "Liability For The Escape 
Of GM Seeds:  Pursuing The 'Victim'?", The Modern Law Review, 2002, Vol. 65, p. 517.   
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In contrast to the patent system, the Plant Breeder's Rights Act 1994 (Cth) provides a number 
of exceptions to ensure that there is reasonable public access to new varieties of plants.  There 
is a much better balance between the interests of owners and users under this regime.  First, 
certain acts done for private, experimental or breeding purposes do not infringe plant breeder's 
rights.25  Second, the conditioning and use of farm saved seed does not infringe plant breeder's 
rights.26  Third, the Plant Breeder's Rights Amendment Bill 2002 (Cth) plans to introduce new 
provisions dealing with equitable remuneration.  This legislative amendment is intended to 
provide legal backing for the scheme of end point royalties.  Fourth, “the grantee of PBR in a 
plant variety must take all reasonable steps to ensure reasonable public access to that plant 
variety."27 The Secretary of the Department of Agriculture, Fisheries and Forestry Australia 
has the power to provide a compulsory license in the appropriate circumstances.28  Finally, the 
Federal Court may refuse to award damages, or make an order for an account of profits, if the 
person satisfies the court that, at the time of the infringement, the person was not aware of, and 
had no reasonable grounds for suspecting the existence of that right.29  Such public interest 
exemptions under plant breeder's rights will be undermined if the scope of the innovation patent 
is expanded to include plant material.  
 
                                                            
25  S 16 of the Plant Breeder's Rights Act 1994 (Cth) 
26  S 17 (1) of the Plant Breeder's Rights Act 1994 (Cth); and Asgrow Seed Company v Winterboer et al 
(1995) 513 US 179. 
27  S 19 (1) of the Plant Breeder’s Rights Act 1994 (Cth) 
28  The case of  Sacker Potatoes Ltd v C Meijer BV  (Unreported, October 31, 2001) considered whether 
compulsory exploitation rights should be granted in protected variety of potato on grounds that refusal to issue 
licence was unreasonable and right holder was failing to satisfy demand in UK market. 
29  S 57 (1) of the Plant Breeder's Rights Act 1994 (Cth) 
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Plant breeders may act under the belief that their conduct is permissible under the Plant 
Breeder's Rights Act 1994 (Cth) - only to discover that they might nonetheless be infringing an 
innovation patent. This lack of consistency between plant breeder's rights and innovation 
patents will give rise to uncertainty, confusion, and misunderstanding amongst rural and 
regional communities. 
 
Furthermore, it should be noted that the Plant Breeder's Rights Act 1994 (Cth) is currently 
subject to the full force of the competition provisions of the Trade Practices Act 1974 (Cth).  
It therefore is much more sensitive to competition policy than the patent system.  The sui 
generis system is not mentioned at present in s 51 (3) of the Trade Practices Act 1974 (Cth), 
which limits the range of competition actions that can be brought with respect of intellectual 
property.  However, the Federal Government has expressed a desire to include plant breeder's 
rights in this regime in the future. 
 
5. Animal Subject Matter 
 
The protection of animal subject matter under patent law has been controversial.  There should 
be reservations as to whether animal breeding should come within the scope of innovation 
patents. 
 
Most notably, there has been ongoing litigation over the transgenic animal, OncoMouse. in the 
European Union.30   The following account derives from a recent press release from the 
European Patent Office (EPO). 
                                                            
30  EPO press release.  "'Oncomouse' opposition proceedings resume at EPO", November 2001, 
http://www.european-patent-office.org/news/pressrel/2001_11_05_e.htm 
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The "oncomouse" application was filed with the EPO in June 1985. Initially, on 14 July 1989, 
the examining division refused the application, inter alia on the grounds that Article 53 (b) of 
the European Patent Convention prohibits European patents on animals per se. The applicant 
appealed against that decision, and on 22 October 1990 an EPO technical board of appeal set 
it aside and sent the case back for re-examination.  
 
The board of appeal held that Article 53(b) EPC rules out patents on animal varieties, not 
animals generally. The examiners therefore had to decide whether the application was for an 
"animal variety" within the meaning of the provision, and also whether to invoke Article 53 (a) 
EPC which prohibits patents for "inventions the publication or exploitation of which would be 
contrary to ordre public or morality".  
 
In a second decision in October 1991, the examining division granted the "oncomouse" patent 
as complying with the EPC, commenting that the patent application's purpose - to facilitate 
cancer research and prevention - was of such importance for humanity as to outweigh any 
disadvantages such as the suffering of the animals concerned.  
 
In 2001, The European Patent Office has resumed opposition proceedings against Harvard 
University's "oncomouse" patent.31 The opposition division in Munich has invited the parties - 
Harvard University as the patent proprietor and 16 different groups, individuals, political 
parties and organisations wanting the patent revoked - to three days of oral proceedings.  
 
                                                            
31  Ibid 
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In light of this controversy, it would be inappropriate to expand the scope of innovation patents 
to include animal subject matter.  Past experience has shown that there is a need for stringent 
examination and re-examination of animal subject matter - as well as the scope for complex 
opposition proceedings.  The innovation patent regime would be a poor framework for animal 
subject matter - especially given the concerns about the lack of substantive examination at the 
stage of registration. 
 
6. International Context 
 
Finally, it should be stressed that the innovation patent need not include plant and animal 
subject matter because of any international obligations or norms.  It must also be recognised 
that there is no consensus as to whether second tier patent protection is appropriate - let alone 
as to what model for such a system would be ideal. 
 
Some commentators have argued that Australia should lift the restrictions on animal and plant 
subject matter in light of international practice.  Notably, Des Ryan argues:   
 
The Agreement on Trade Related Aspects of Intellectual Property provides by Article 27 (3) that member 
states may exclude from patentability, plants, animals and other micro-organisms and essentially 
biological processes for their production.  The European Patent Convention contains a provision to that 
effect.  In its negotiations and discussions, until recently, Australia has taken a position in favour of the 
restriction or elimination of this possibility of this exclusion from Article 27 (3) of the TRIPs Agreement.  
The position was taken, I believe, principally on the basis that Australia does rather better in the biological 
and medical sciences than it does in other areas, and notwithstanding such subterfuges as the "Swiss 
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type" claim, Australian industries had been disadvantaged by the exclusion from the European patent 
particularly, in the field of plant biology.32 
 
However, it is a mistake to confuse a negotiating position with international obligations.  The 
World Trade Organization negotiations at Doha in 2001 have not resolved whether there should 
be a revision of Article 27 (3) of the TRIPS Agreement.  Furthermore it is also misleading to 
there is no protection for plant subject matter in the European Union in the absence of patent 
protection.  Obviously this overlooks the important role played by plant breeder's rights. 
 
The European Union provides under the Biotechnology Directive that a patent shall not be 
granted for "any variety of animal or plant or any essentially biological process for the 
production of animals or plants, not a being a microbiological process or other technical process 
or the product of such a process".  The first form of subject matter excluded from protection 
are "animal varieties".  The meaning of "animal varieties" has been considered in the 
OncoMouse decision.  The second form of biological subject matter that is excluded from the 
scope of protection is "plant varieties".  Lionel Bently and Brad Sherman comment in 
Intellectual Property Law:  "In order to ensure that plant breeders were not able to obtain patent 
protection and plant variety protection, it was decided that the two conventions should be 
mutually exclusive:  a person could be given either a sui generis plant breeder's right or patent 
protection, but not both".33   The Enlarged Board of Appeal of the European Patent Office 
affirmed in the Novartis decision that the extent of the exclusion for plants is the obverse of 
                                                            
32  Ryan, D.  "Innovation Patents - What Is There Likely Impact?", Intellectual Property Forum, March 
2002, Issue 48, p 30. 
33  Bently, L. and Sherman, B.  Intellectual Property Law.  Oxford: Oxford University Press, 2001, p. 396. 
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the availability of plant variety rights and that plant varieties are only granted for specific plant 
varieties.34 
 
The United States of America is unique because it had established a system of plant patents 
prior to the implementation of a legislative regime for plant varieties. It can therefore be 
distinguished from the situation of Australia. In JEM Ag Supply Inc v Pioneer Hi-Bred 
International Inc, the United States Supreme Court found that newly developed plant breeds 
can receive utility patents - as well as plant breeder's rights and plant patents.35 This case is 
only of academic interest.  It certainly cannot be used to support the expansion of the innovation 
patent system in the context of Australia. 
 
Given this international context, there is no need for Australia to expand the scope of the 
innovation patent to include animal and plant subject matter because of international 
obligations or the practice of other national jurisdictions.  Furthermore there is no demand for 
Australia to change its laws out of a desire for harmonisation.  Quite clearly, there is no 
international norm as to the appropriate interaction between plant breeder's rights and patent 
law - especially given the wide divergence in the approaches of the European Union and the 
United States of America. 
 
Moreover, it should be noted that there is not even any international consensus regarding 
second tier patent protection.  A Harvard International Journal article on "Second Tier Patent 
Protection" conducts an international survey of second tier patent proposals in Europe, 
                                                            
34  Novartis/ Transgenic Plant (T1054/96) [1999] EPOR 123 
35  JEM Ag Supply Inc v Pioneer Hi-Bred International Inc (2001) 534 US 124 
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Australia, and the United States.36  Mark Janis comments that "modern second tier patent 
proposals, including both the European and Australian initiatives, are ill-considered, and that 
Europe, Australia, and the United States would all be better served by directing energies 
towards the reform of regular patent law, and towards the exploration of alternative avenues 
for protecting incremental innovation".37 
 
Conclusion 
 
ACIPA submits that there are strong justifications for the exclusion of plant and animal subject 
matter from the scope of the innovation patent.  It maintains that such subject matter is much 
better accommodated under the plant breeder's rights system. 
 
At the outset, ACIPA first notes that there have been doubts raised about the constitutional 
validity of both innovation patents.  By contrast, the High Court has confirmed that the plant 
breeder's rights system is a valid exercise of legislative power. 
 
Second, ACIPA observes that there are manifold problems with the registration of innovation 
patents - in particular, with the lack of substantive examination.  It maintains that the system 
of plant breeder's rights has much more legitimacy and credibility.  Third, ACIPA comments 
that the standard of an "innovative step" will create confusion and uncertainty in respect of 
plant subject matter.  The standards of distinctiveness, uniformity, and stability under the plant 
breeder's rights regime are much better adapted to the needs of plant breeders.  Fourth, ACIPA 
observes that the innovation patent regime will have a deleterious impact upon regional and 
                                                            
36  Janis, M.  "Second Tier Patent Protection", Harvard International Law Journal, 1999, Vol. 40, p. 151. 
37  Ibid. 
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rural communities.  It maintains that the plant breeder's rights regime has a much better balance 
through the range of exceptions and exemptions.  
 
Fifth, ACIPA comments upon the controversy that has attended patent protection of animal 
subject matter.  In such circumstances, it would be sensible to exclude animal subject matter 
from the scope of the innovation patent.  Sixth, ACIPA notes that Australia is not compelled 
to provide concurrent protection of plant and animal subject matter under its international 
obligations.  It observes that the exclusion of such subject matter from the scope of innovation 
patents is in step with international practice. 
 
In conclusion, ACIPA questions the wisdom of conducting an ad hoc review of the exclusion 
of plant and animal subject matter from the scope of the innovation patent, so soon after the 
legislative process has finished.  In his second reading speech, the Honourable Warren Entsch 
observed:   
 
Although innovation patents will be available for most of the types of invention currently covered by 
standard patents, they will not be available for plants and animals, or biological processes for the 
generation of plants and animals. This exclusion does not include microbiological processes and 
innovation patents will be available for processes such as cheese and wine making and the synthesis of 
industrial compounds using micro-organisms.38 
 
                                                            
38  Entsch, Warren, MP (Leichhardt, Parliamentary Secretary to the Minister for Industry, Science and 
Resources, LP, Government).  "Second Reading Speech on the Patents Amendment (Innovation Patent) Bill 2000 
(Cth)", House Hansard, 29 June 2000, p. 18583. 
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It would be premature to revisit the legislative compromises and the political decisions that 
took place in respect of the Patent Amendment (Innovation Patent) Act 2000 (Cth), and second 
guess the will of Parliament on this topic.  ACIPA advises that a comprehensive review of the 
innovation patent system is necessary after an appropriate period of time has elapsed.  A proper 
review of all aspects of the new registration system should be conducted - rather than an 
examination of a single issue in isolation. 
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SUPPLEMENTARY SUBMISSION TO THE ACIP INQUIRY INTO THE 
INNOVATION PATENT - EXCLUSION OF PLANT AND 
ANIMAL SUBJECT MATTER 
MATTHEW RIMMER 
 
The Australian Centre for Intellectual Property in Agriculture (ACIPA) is a research centre 
based at the law schools of the Australian National University in Canberra and Griffith 
University in Brisbane.  It commenced operations in September 2000 to undertake research in 
issues relating to intellectual property law, and apply that knowledge to the scientific 
community and industry and rural bodies. The Centre's ultimate purpose is to foster an active 
environment in which Australia better protects and capitalises the products of research and 
innovation.   It has particular expertise in both patent law and plant breeder's rights. 
 
ACIPA made an initial submission to the Advisory Council on Intellectual Property in relation 
to the "innovation patent - exclusion of plant and animal subject matter".  It also participated 
in the round-table discussion at Stamford Plaza on the 18 June 2003.  ACIPA welcomes the 
opportunity to make a supplementary submission to the Advisory Council on Intellectual 
Property in respect of the "innovation patent - exclusion of plant and animal subject matter".  
It has ten main points. 
 
1. ACIPA supports the submission of AFFA that the initial issues paper and the roundtable 
discussion provided an inadequate basis for a consideration of the exclusion of plant and animal 
subject matter from the innovation patent.  The discussion of plant breeders rights was notably 
poor.  In particular, it was a concern that there was no cost/ benefit analysis of the proposed 
changes to the law in line with the competition policy of the Government. 
24 
 
2. ACIPA advises that a comprehensive review of the innovation patent system is 
necessary after a suitable period of time has elapsed.  In particular, a number of deficiencies in 
the regime need to be addressed - including the lack of substantive examination, the vagueness 
of an innovative step, and the paucity of defences.  
 
3. ACIPA comments that the discussion over the innovation patent, and the exclusion of 
plant and animal subject matter, needs to be better co-ordinated with the larger Australian Law 
Reform Commission inquiry into gene patenting. 
 
4. ACIPA notes that there was widespread industry dissatisfaction in the submissions and 
the round-table discussion with the registration system for the innovation patent.  The empirical 
evidence suggested that only 10 per cent of innovation patents were being substantively 
examined - whether by the instigation of the applicant or the commissioner of the patents.  Such 
a low rate of substantive examination devalues the system of innovation patents as a vehicle 
for commercialisation and investment. 
 
5. ACIPA acknowledges the concern expressed in the submissions and at the roundtable 
discussion that the threshold of an "innovative step" for an innovation patent was vague and 
uncertain. It notes the evidence of the registrar of the Plant Breeders' Rights Office that the 
majority of applications for plant breeders' rights would also satisfy the requirements for an 
innovation patent.  ACIPA observes that this would result in a clear-cut conflict between the 
two regimes.  It also casts doubt on the Advisory Council's schematic representation of plant 
breeders' rights, innovation patents, and standard patents as a tiered, hierarchal order. 
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6. ACIPA has grave concerns that the extension of the innovation patent to include plant 
subject matter would jeopardise a number of important defences under plant breeders' rights - 
most notably, farm-saved seed.  Conflicts already exist in relation to the interaction between 
standard patents and plant breeders' rights.  ACIPA also expresses doubts about the legality of 
using private contracts and terminator technologies to oust defences under plant breeders' 
rights. It is important that the Advisory Council on Intellectual Property recognise the political 
support for such defences amongst rural and regional constituencies of the Federal 
Government. 
7. ACIPA comments that there is no universal acceptance of a second-tier patent system.  
As a result, it would be very difficult to commercialise innovation patents in other jurisdictions.  
ACIPA recommends that the plant breeders' rights system is a much better system for the 
commercialisation of plant innovations because of the international framework established 
under the UPOV convention. 
 
8. ACIPA concludes that the plant breeders' rights regime is the most appropriate legal 
regime to deal with plant innovations.  It recommends that the innovation patent should 
continue to exclude plant subject matter, especially in light of the dearth of empirical evidence 
or industry support for its inclusion. 
 
9. ACIPA supports the submission of the Australian Institute of Marine Sciences that the 
inclusion of microbiological processes within the scope of the innovation patent is problematic. 
 
10. ACIPA notes that industry specific conventions exist for animal breeding.  The 
extension of the innovation patent to animal breeding could cause great concern amongst a 
number industries - such as kennel clubs, horse racing, and livestock producers.  ACIPA 
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supports the submission of AFFA that there is no industry support for the extension of the 
innovation patent to animal breeding. 
 
